PNT Stock Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
POINT Biopharma Global Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$12.50 |
52 Week High | US$14.35 |
52 Week Low | US$6.57 |
Beta | -0.0026 |
1 Month Change | -9.49% |
3 Month Change | 87.41% |
1 Year Change | 75.07% |
3 Year Change | -10.20% |
5 Year Change | n/a |
Change since IPO | 3.99% |
Recent News & Updates
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12Shareholder Returns
PNT | US Biotechs | US Market | |
---|---|---|---|
7D | 0.2% | 0.02% | 1.2% |
1Y | 75.1% | 6.7% | 20.6% |
Return vs Industry: PNT exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: PNT exceeded the US Market which returned 24.8% over the past year.
Price Volatility
PNT volatility | |
---|---|
PNT Average Weekly Movement | 24.6% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PNT's share price has been volatile over the past 3 months.
Volatility Over Time: PNT's weekly volatility has increased from 13% to 25% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 129 | Joe McCann | www.pointbiopharma.com |
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies.
POINT Biopharma Global Inc. Fundamentals Summary
PNT fundamental statistics | |
---|---|
Market cap | US$1.33b |
Earnings (TTM) | US$96.55m |
Revenue (TTM) | US$243.69m |
13.8x
P/E Ratio5.5x
P/S RatioIs PNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PNT income statement (TTM) | |
---|---|
Revenue | US$243.69m |
Cost of Revenue | US$0 |
Gross Profit | US$243.69m |
Other Expenses | US$147.14m |
Earnings | US$96.55m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.91 |
Gross Margin | 100.00% |
Net Profit Margin | 39.62% |
Debt/Equity Ratio | 0% |
How did PNT perform over the long term?
See historical performance and comparison